Sulfadoxine-Pyrimethamine Exhibits Dose-Response Protection Against Adverse Birth Outcomes Related to Malaria and Sexually Transmitted and Reproductive Tract Infections


Chico, RM; Chaponda, EB; Ariti, C; Chandramohan, D; (2017) Sulfadoxine-Pyrimethamine Exhibits Dose-Response Protection Against Adverse Birth Outcomes Related to Malaria and Sexually Transmitted and Reproductive Tract Infections. Clinical infectious diseases, 64 (8). pp. 1043-1051. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/cix026

This is the latest version of this item. Earlier version may have full text manuscript

[img]
Preview
Text - Published Version
License:

Download (154kB) | Preview
[img]
Preview
Text - Supplemental Material
License:

Download (179kB) | Preview
[img]
Preview
Text - Supplemental Material
License:

Download (256kB) | Preview
[img]
Preview
Text - Supplemental Material
License:

Download (254kB) | Preview
[img]
Preview
Text - Supplemental Material
License:

Download (254kB) | Preview
[img]
Preview
Text - Supplemental Material
License:

Download (254kB) | Preview
[img]
Preview
Text - Supplemental Material
License:

Download (254kB) | Preview

Abstract

: We conducted a prospective cohort study in Zambia among pregnant women who received intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP).<br/> : We calculated the odds ratios (ORs) of adverse birth outcomes by IPTp-SP exposure, 0-1 dose (n = 126) vs ≥2 doses (n = 590) and ≥2 doses (n = 310) vs ≥3 doses (n = 280) in 7 categories of malaria infection and sexually transmitted and reproductive tract infections (STIs/RTIs).<br/> : We found no significant differences in baseline prevalence of infection across IPTp-SP exposure groups. However, among women given 2 doses compared to 0-1 dose, the odds of any adverse birth outcome were reduced 45% (OR, 0.55; 95% confidence interval [CI], 0.36, 0.86) and 13% further with ≥3 doses (OR, 0.43; 95% CI, 0.27, 0.68). Two or more doses compared to 0-1 dose reduced preterm delivery by 58% (OR, 0.42; 95% CI, 0.27, 0.67) and 21% further with ≥3 doses (OR, 0.21; 95% CI, 0.13, 0.35). Women with malaria at enrollment who received ≥2 doses vs 0-1 had 76% lower odds of any adverse birth outcome (OR, 0.24; 95% 0.09, 0.66), and Neisseria gonorrhoeae and/or Chlamydia trachomatis had 92% lower odds of any adverse birth outcome (OR, 0.08; 95% CI, 0.01, 0.64). Women with neither a malaria infection nor STIs/RTIs who received ≥2 doses had 73% fewer adverse birth outcomes (OR, 0.27; 95% CI, 0.11, 0.68).<br/> : IPTp-SP appears to protect against malaria, STIs/RTIs, and other unspecified causes of adverse birth outcome.<br/>

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID: 28329383
Web of Science ID: 397809800007
URI: http://researchonline.lshtm.ac.uk/id/eprint/3682761

Available Versions of this Item

Statistics


Download activity - last 12 months
Downloads since deposit
74Downloads
96Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item